Active Research
-
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Primary Investigator: Albritton MD, Karen
IRB ID: 2023-034 (OPEN)
-
A PHASE 2 STUDY OF DS-8201A (NSC# 807708, IND# 153036) IN ADOLESCENTS, OR YOUNG ADULTS WITH RECURRENT HER2+ OSTEOSARCOMA
Primary Investigator: Vallance MD, Kelly
IRB ID: 2021-086 (TEMPORARILY CLOSED TO ACCRUAL)
-
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Primary Investigator: Albritton MD, Karen
IRB ID: 2022-122 (OPEN)
-
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-C) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR RMS)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2021-083 (TEMPORARILY CLOSED TO ACCRUAL)
-
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Primary Investigator: Vallance MD, Kelly
IRB ID: 2017-030 (OPEN)
-
ARAR2221: A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
Primary Investigator: Greer MD, Chelsee
IRB ID: 2024-071 (OPEN)
-
AREN2231: Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2025-046 (OPEN)
-
CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research
Primary Investigator: Vallance MD, Kelly
IRB ID: 2020-066 (OPEN)
-
JMML Haplo Project
Primary Investigator: Eames MD, Gretchen
IRB ID: 2025-082 (OPEN)
-
Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma (ARST2032)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2022-072 (OPEN)
-
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2020-097 (OPEN)